AXSM - Axsome TherapeuticsEPS of -$0.26 revenue of $94.6M beats by $69.12M

2023-05-08 07:03:54 ET

• Axsome Therapeutics press release ( NASDAQ: AXSM ): Q1 EPS of -$0.26 may not be comparable to consensus of -$1.29.
• Revenue of $94.6M beats by $69.12M .

• Auvelity 1Q 2023 net product sales of $15.7 million

• Total 1Q 2023 net product sales of $28.6 million

• Total 1Q 2023 revenue of $94.6 million, including Sunosi ex-U.S. license agreement upfront payment

• Cash and cash equivalents totaled $246.5 million at March 31, 2023, compared to $200.8 million at December 31, 2022.
• Axsome believes that its current cash, along with the remaining committed capital from the $350 million term loan facility, is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.

For further details see: